Novartis's Cosentyx Fails To EXCEED Humira in PsA
'Narrowly Missed' Statistical Significance
The Swiss major's immunology head tells Scrip that while Cosentyx was unable to beat Humira on the 20% improvement scale for symptoms in psoriatic arthritis patients, the totality of the data from the EXCEED study should sway clinicians to use the IL-17 inhibitor as a first-line treatment.
